IPilogue

MARCH 9, 2023

This article was written as a requirement for Prof. Health Canada, in a joint effort with the US Food and Drug Administration and the U.K. Mac Mok is a 3L JD candidate at Osgoode Hall Law School. Pina D’Agostino’s IP Intensive Program. Artificial intelligence (AI) systems have entered every facet of our daily lives.

IP 103

IP Designs Design Law 103

Patently-O

NOVEMBER 29, 2023

He has an extensive background in chemistry, food science, and viticulture. Article III standing remains a hot topic at all levels of federal litigation and across many different areas of law. The Federal Circuit dismissed Allgenesis’s appeal because Allgenesis failed to establish Article III standing to appeal.

Art 49

Art Business Patent Settlement 49

Fish & Richardson Trademark & Copyright Thoughts

MARCH 8, 2021

Fish attorneys Jenny Shmuel , Philip Chen , and Kayleigh McGlynn authored a Biosimilar Development article, “ Regulatory And Legislative Actions Set The Tone For Biosimilars In 2021.” This article focuses on regulatory and legislative actions in 2020 that may impact the burgeoning biosimilars space in 2021 and beyond.

Settlement 40

Settlement Licensing Designs Design 40

Fish & Richardson Trademark & Copyright Thoughts

JANUARY 11, 2022

The continued slow pace of approvals is potentially the result of the COVID-19 pandemic and related delays in clinical trials and facility inspections by FDA, as well as a re-prioritization and shifting of agency resources towards COVID-19 vaccines and treatments. Introduction. Biosimilar Approvals and Launches in 2021. BPCIA Litigation.

Litigation 52

Litigation Settlement Patent Marketing 52